785779-33-1

Usage

Bromo-substituted derivative of benzene

A benzene ring with a bromine atom attached as a substituent.

Iodopropyl group attached to the fourth carbon atom

A three-carbon propyl chain with an iodine atom attached to the third carbon, connected to the fourth carbon of the benzene ring.

Common use as a reagent in organic synthesis

Widely utilized in the formation of biaryl compounds and other aromatic derivatives.

Application as an intermediate in the production of pharmaceuticals, agrochemicals, and other organic compounds

Serves as a precursor in the synthesis of various chemical products, including medications and agricultural chemicals.
A visually transparent liquid lacking color and having a subtle, sweet-smelling fragrance.

Hazardous substance

Possesses properties that pose potential risks to health and safety.

Flammability

Can easily catch fire and burn, creating a fire hazard.

Potential for causing skin and eye irritation

May lead to redness, itching, or other forms of irritation upon contact with the skin or eyes.

Upstream product

• 25574-11-2 3-(4-bromophenyl)propanol 
• 1643-30-7 3-(4-bromophenyl)propionic acid 

Downstream Products

• 1361990-89-7 3,7-bis((3-(4-bromophenyl)propyl)(methyl)amino)phenothiazin-5-ium iodide 
• 886763-02-6 3-(4-bromophenyl)-N-methylpropan-1-amine 
• 126930-71-0 1-bromo-4-undecylbenzene 
• 1333170-78-7 (6S)-2-nitro-6-(3-{4-[5-trifluoromethyl-2-pyridinyl]phenyl}propoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1333170-77-6 (6S)-2-nitro-6-(3-{4-[6-trifluoromethyl-3-pyridinyl]phenyl}propoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1333170-76-5 (6S)-2-nitro-6-{3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]propoxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1333170-75-4 (6S)-6-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1333170-74-3 (6S)-2-nitro-6-{3-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]propoxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1333171-30-4 (6S)-6-[3-(4-bromophenyl)propoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 

Relevant academic research and scientific papers

Introduction of Cyclopropyl and Cyclobutyl Ring on Alkyl Iodides through Cobalt-Catalyzed Cross-Coupling

A cobalt-catalyzed cross-coupling between alkyl iodides and cyclopropyl, cyclobutyl, and alkenyl Grignard reagents is disclosed. The reaction allows the introduction of strained rings on a large panel of primary and secondary alkyl iodides. The catalytic system is simple and nonexpensive, and the reaction is general, chemoselective, and diastereoconvergent. The alkene resulting from the cross-coupling can be transformed to substituted cyclopropanes using a Simmons-Smith reaction. The formation of radical intermediates during the coupling is hypothesized.

Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

New analogues of antitubercular drug PA-824 were synthesized, featuring alternative side chain ether linkers of varying size and flexibility, seeking drug candidates with enhanced metabolic stability and high efficacy. Both α-methyl substitution and removal of the benzylic methylene were broadly tolerated in vitro, with a biaryl example of the latter class exhibiting an 8-fold better efficacy than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection and negligible fragmentation to an alcohol metabolite in liver microsomes. Extended linkers (notably propenyloxy, propynyloxy, and pentynyloxy) provided greater potencies against replicating M. tb (monoaryl analogues), with propynyl ethers being most effective under anaerobic (nonreplicating) conditions (mono/biaryl analogues). For benzyloxybenzyl and biaryl derivatives, aerobic activity was maximal with the original (OCH2) linker. One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model.

Structure-based optimization of FDA-approved drug methylene blue as a c-myc G-quadruplex DNA stabilizer

G-quadruplexes are non-canonical DNA secondary structures putatively present in the promoter regions of oncogenes in the human genome. The targeting of promoter G-quadruplex structures to repress oncogene transcription represents a potential anticancer st